Showing 5121-5130 of 21466 results for "".
- Vasopressors or Fluids in Early Septic Shockhttps://reachmd.com/news/vasopressors-or-fluids-in-early-septic-shock/2487606/The optimal approach to early resuscitation in septic shock remains uncertain, with ongoing equipoise between the use of larger volumes of intravenous fluids to restore perfusion and the use of early vasopressor therapy with smaller fluid volumes to minimize potential harm from excess fluid
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://reachmd.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- Nonsurgical vs Surgical ACL Care: Knee Function and Return to Sporthttps://reachmd.com/news/nonsurgical-vs-surgical-acl-care-knee-function-and-return-to-sport/2487599/Key Takeaways No statistically significant between-group difference appeared in IKDC-SKF at any measured time point, and scores improved over time in both groups. Seventy-five percent of the cohort returned to sport within 24 months, with similar 24-mo
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://reachmd.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es
- Meta-Analysis Links Heart Failure Therapies to Better Cardiac Function During Cancer Treatmenthttps://reachmd.com/news/heart-failure-cardiac-cancer-treatment/2487586/Key Takeaways RAAS inhibition plus beta blockers was associated with the largest reported LVEF gain among the more commonly studied therapies. RAAS inhibitors, beta blockers, and their combination were also associated with improved global longitudinal strain
- Robotic Versus Laparoscopic Radical Nephroureterectomy in UTUChttps://reachmd.com/news/robotic-laparoscopic-radical-nephroureterectomy-utuc-t3-ivr-signal/2487585/Key Takeaways Perioperative outcomes were comparable, and no remarkable differences were reported in disease-free or overall survival. Surgical platform was not significantly associated with cancer-specific mortality or intravesical recurrence in the o
- Skin Cancer Champions Earns Two Digital Health Awards for Patient Education and Community Engagementhttps://reachmd.com/news/skin-cancer-champions-earns-two-digital-health-awards-for-patient-education-and-community-engagement/2487580/Skin Cancer Champions, an online community dedicated to supporting patients and caregivers affected by non-melanoma skin cancers, has received two Bronze Awards in the Spring 2026 Digital Health Awards, presented by the Health Information Resource Center (HIRC). The awards recognize the or
- BOTOX Cosmetic Names 2026 Confidence Collective Entrepreneur Cohorthttps://reachmd.com/news/botox-cosmetic-names-2026-confidence-collective-entrepreneur-cohort/2487577/Allergan Aesthetics, an AbbVie company, has announced the 2026 cohort for The Confidence Collective: Empowering Women Entrepreneurs, a BOTOX® Cosmetic initiative designed to support women business owners through mentorship, education, and funding opportunities. According to the company, th
- Aglatimagene Besadenovec Plus Radiotherapy in Localized Prostate Cancerhttps://reachmd.com/news/aglatimagene-besadenovec-plus-radiotherapy-in-localized-prostate-cancer/2487557/Key Takeaways Longer disease-free survival was observed with aglatimagene besadenovec added to radiotherapy than with placebo. The phase 3, randomized, double-blind, placebo-controlled trial delivered CAN-2409 intraprostatically alongside radiotherapy.
- Lorlatinib in Previously Treated Alk-Positive Metastatic Nsclchttps://reachmd.com/news/lorlatinib-in-previously-treated-alk-positive-metastatic-nsclc/2487571/Patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) have benefited significantly from the evolution of targeted therapies, yet treatment decisions become increasingly challenging once disease progresses after second-generation ALK tyrosine kinase inhibitors (TKIs). New